A Syracuse biotech betting that a single injection can suspend cancer, quiet the pain, and rebuild the bone the disease destroys.
When cancer spreads to bone, the usual story is one of management, not repair. Tumors carve holes in the skeleton - osteolytic lesions - and the standard of care aims to slow that damage and dull the pain. Roughly 330,000 Americans live with some form of bone metastases each year. Zetagen Therapeutics, a small clinical-stage biopharmaceutical company operating out of Syracuse, New York, is chasing a different ending: a single, locally-delivered injection designed to suspend the tumor, inhibit pain, and regenerate the bone that was lost.
The company was founded in 2015, spun out of bone-biology research at SUNY Upstate Medical University. Its two scientific founders - Bryan Margulies, PhD, and Nikhil Thakur, MD - were assistant professors there when the underlying discovery emerged. What they found was not a new molecule but a new molecular pathway: a way to redirect a small-molecule drug, one already FDA-approved since 1971, toward three simultaneous jobs in the bone microenvironment.
That distinction matters. Much of biotech's risk lives in novel chemistry - unknown toxicity, unpredictable metabolism, years of safety work. By building on a molecule with a half-century of clinical history, Zetagen reframed its central bet from "is this compound safe?" to "does this pathway do what we think?" The U.S. Food and Drug Administration has since recognized the approach with multiple Breakthrough Designations, a signal that regulators consider the potential benefit worth an accelerated look.
Existing options for bone metastases largely fall into two camps. Bone-modifying agents like bisphosphonates and denosumab slow skeletal-related events. Radiation and radiopharmaceuticals target pain and tumor burden systemically. Both help - neither is designed to refill the cavity a lytic lesion leaves behind.
Zetagen's pitch sits in that gap. Its lead candidate, ZetaMet (Zeta-BC-003), is delivered by a single fluoroscopy-guided intratumoral injection while the patient is under sedation - minutes in an outpatient setting rather than repeated systemic dosing. The therapy is built to act locally at the lesion: hold the tumor, reduce pain, and stimulate the regrowth of healthy trabecular bone. In the company's Phase 2a study, treated lesions showed full bone regeneration with reconstitution of trabecular bone and no skeletal-related events, with mean lesion defect volume decreasing by 87.9% at day 180.
A simplified read of Zetagen's reported Phase 2a signal: the share of lesion defect volume remaining over the six months following a single ZetaMet injection. Figures are the company's own reported measures and should be read as early-stage, small-cohort data.
READ: An 87.9% mean reduction in lesion defect volume at day 180 - the orange bar is what remained. Interim value shown for visual context only.
At the core is the Zeta Platform - a proprietary osteoconductive and osteopromotive drug-eluting carrier that delivers small-molecule therapy locally while promoting bone regeneration. From that engine, Zetagen has pointed candidates at several cancer types.
Bars are indicative of relative stage, not precise regulatory milestones.
The Zeta pathway is designed to suspend cancer growth locally within the bone lesion rather than relying solely on systemic circulation.
Cancer-related bone pain is a defining burden for patients. ZetaMet is built to address it at the source, in the treated lesion.
Rather than only slowing damage, the platform stimulates osteogenic regrowth - reconstituting trabecular bone where the lesion was.
A single fluoroscopy-guided injection under sedation, in an outpatient setting - a contrast to repeated systemic regimens.
Zetagen is a B2B, clinical-stage developer. It funds research through venture rounds and non-dilutive support, advancing patented drug-device candidates through FDA trials toward eventual commercialization or partnership. With around nine employees, it is a lean, science-led operation seated at the CNY Biotech Accelerator in Syracuse.
Its funding tells the arc: a $9.79M Series B in 2023 backed by New York Ventures and Consolidated Capital Investments, followed by an oversubscribed $12.9M Series B1 in November 2025 led by JSTAR Capital Investments - closed, notably, on the strength of Phase 2a data rather than a pitch alone. Total reported funding sits north of $42M.
In the market, Zetagen sits alongside systemic bone-metastasis therapies - bisphosphonates, denosumab, radiopharmaceuticals, radiation - and orthopedic bone-void fillers. Its differentiation is the combination: a single local intervention aimed at the lesion and at bone regeneration, not only at slowing skeletal events.
The customers, ultimately, are Stage 4 cancer patients and the oncologists, interventional radiologists, and orthopedic surgeons who treat them. Near term, the stakeholders are trial sites, investors, and the larger pharma and med-device players who could one day partner or license.
Serial medical-device executive with tenures at Stryker, NuVasive, US Surgical, and Pfizer/Leibinger. Brought commercial and go-to-market experience to a science-first startup.
Chief Scientific Officer with 25+ peer-reviewed publications in bone-cancer biology and tumor reduction. The science originated in his SUNY Upstate research.
Chief Medical Officer and practicing spine specialist with over a decade of orthopedic surgical experience, grounding the platform in clinical reality.
Spun out of bone-biology research at SUNY Upstate Medical University by two assistant professors.
A veteran of Stryker and NuVasive takes the helm in January to carry the science toward market.
SUNY Upstate highlights the technology's ability to rapidly stimulate high-quality bone growth.
Round backed by New York Ventures and Consolidated Capital Investments.
USPTO composition-of-matter patents, completed Phase 2a enrollment, and an oversubscribed $12.9M Series B1.
Preliminary Phase 2a results reporting complete response in metastatic breast cancer bone lesions.
It is a clinical-stage biopharmaceutical company developing locally-administered therapies for cancers that spread to bone, aiming to suspend the tumor, inhibit pain, and regenerate bone with a single injection.
ZetaMet (Zeta-BC-003) is Zetagen's lead candidate for metastatic breast cancer lytic bone lesions, delivered via a single fluoroscopy-guided intratumoral injection.
It was founded in 2015 and is headquartered in Syracuse, New York, having spun out of SUNY Upstate Medical University.
Publicly disclosed rounds include a $9.79M Series B (2023) and an oversubscribed $12.9M Series B1 (2025), with total funding reported around $42M.
It completed Phase 2a enrollment for ZetaMet, reported an 87.9% mean reduction in lesion defect volume at day 180, holds multiple FDA Breakthrough Designations, and presented results at the 2025 San Antonio Breast Cancer Symposium.
Note: Clinical figures are the company's reported early-stage results and are not a substitute for peer-reviewed data or medical advice.